Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553442 | 0.85 | RIPK1 (0.47) | GRM2RIPK1TDP1KDM1ACTSS | |
| SCHEMBL3640549 | 0.85 | AOC3 (0.47) | AOC3TAAR1TDP1CTSSCTSK | |
| SCHEMBL14326997 | 0.84 | TAAR1 (0.50) | AOC3TAAR1GRM2CHRM5CHRM1 | |
| SCHEMBL2257781 | 0.82 | AOC3 (0.43) | AOC3TAAR1GRM2CHRM5CHRM1 | |
| SCHEMBL9535128 | 0.80 | TAAR1 (0.42) | AOC3TAAR1GRM2CHRM5CHRM1 | |
| SCHEMBL25047643 | 0.80 | CA12 (0.43) | AOC3TAAR1GRM2 | |
| SCHEMBL31407335 | 0.79 | TAAR1 (0.41) | AOC3TAAR1GRM2CHRM5CHRM1 | |
| SCHEMBL3437118 | 0.78 | TAAR1 (0.44) | AOC3TAAR1GRM2CHRM5CHRM1 | |
| SCHEMBL9103295 | 0.78 | NPY5R (0.45) | AOC3TAAR1MCHR1RIPK1 | |
| SCHEMBL25047599 | 0.78 | CA14 (0.45) | AOC3TAAR1GRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| EP-2288602-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| EP-2185522-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009020580-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | AOC3 4563/4885TAAR1 4367/4885GRM2 167/4885 |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | AOC3 392/4885TAAR1 567/4885GRM2 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.